• By ICR Secretariat
  • Posted Thursday, August 18, 2022

2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again

https://www.fiercepharma.com/pharma/two-deaths-after-novartis-zolgensma-bring-gene-therapys-liver-safety-spotlight-again

Novartis has recorded two deaths after treatment with its spinal muscular atrophy gene therapy Zolgensma, once again bringing gene therapy’s safety into attention.